Molecular markers of breast axillary lymph node metastasis

References

• Berry DA, Cronin KA, Plevritis SK et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N. Engl. J. Med.353(17), 1784–1792 (2005).
   PubMed Web of Science ®Google Scholar
• Olopade OI, Grushko TA, Nanda R, Huo D. Advances in breast cancer: pathways to personalized medicine. Clin. Cancer Res.14(24), 7988–7999 (2008).
   PubMed Web of Science ®Google Scholar
• Jemal A, Siegel R, Ward E et al. Cancer statistics, 2008, CA Cancer J. Clin.58(2), 71–96 (2008).
   PubMed Web of Science ®Google Scholar
• Michaelson JS, Silverstein M, Sgroi D et al. The effect of tumor size and lymph node status on breast carcinoma lethality. Cancer98(10), 2133–2143(2003).
   PubMed Web of Science ®Google Scholar
• Hayes DF. Prognostic and predictive factors revisited. Breast14(6), 493–499 (2005).
   PubMed Web of Science ®Google Scholar
• Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thürlimann B, Senn HJ. 10th St. Gallen conference. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann. Oncol.18(7), 1133–1144 (2007).
   PubMed Web of Science ®Google Scholar
• Henry NL, Hayes DF. Uses and abuses of tumor markers in the diagnosis, monitoring, and treatment of primary and metastatic breast cancer. Oncologist11(6), 541–552 (2006).
   PubMed Web of Science ®Google Scholar
• Erven K, Van Limbergen E. Regional lymph node irradiation in breast cancer. Future Oncol.3(3), 343–352 (2007)
   PubMedGoogle Scholar
• Heimann R, Lan F, McBride R, Hellman S. Separating favorable from unfavorable prognostic markers in breast cancer: the role of E-cadherin. Cancer Res.60(2), 298–304 (2000).
   PubMed Web of Science ®Google Scholar
• Heimann R, Hellman S. Clinical progression of breast cancer malignant behavior: what to expect and when to expect it. J. Clin. Oncol.18(3), 591–599 (2000).
   PubMed Web of Science ®Google Scholar
• Bollet MA, Kirova YM, Antoni G et al. Response to concurrent radiotherapy and hormone-therapy and outcome for large breast cancers in post-menopausal women. Radiother. Oncol.85(3), 336–345 (2007).
   PubMed Web of Science ®Google Scholar
• Finek J, Holubec L Jr, Topolcan O, Elgrova L, Skalova A, Pecen L. The importance of prognostic factors in premenopausal women with breast cancer. Anticancer Res.27(4A), 1893–1896 (2007).
   PubMed Web of Science ®Google Scholar
• Pettinato G, Manivel CJ, Panico L, Sparano L, Petrella G. Invasive micropapillary carcinoma of the breast: clinicopathologic study of 62 cases of a poorly recognized variant with highly aggressive behavior. Am. J. Clin. Pathol.121(6), 857–866 (2004).
   PubMed Web of Science ®Google Scholar
• Kim KJ, Huh SJ, Yang JH et al. Treatment results and prognostic factors of early breast cancer treated with a breast conserving operation and radiotherapy. Jpn. J. Clin. Oncol.35(3), 126–133 (2005).
   PubMed Web of Science ®Google Scholar
• Colleoni M, Rotmensz N, Maisonneuve P et al. Prognostic role of the extent of peritumoral vascular invasion in operable breast cancer. Ann. Oncol.18(10), 1632–1640 (2007).
   PubMed Web of Science ®Google Scholar
• Marinho VF, Metze K, Sanches FS, Rocha GF, Gobbi H. Molecular features of breast cancer predictive of lymph node metastases. Rev. Assoc. Med. Bras.54(3), 203–207 (2008).
   PubMed Web of Science ®Google Scholar
• Patani NR, Dwek MV, Douek M. Predictors of axillary lymph node metastasis in breast cancer: a systematic review. Eur. J. Surg. Oncol.33(4), 409–419 (2007).
   PubMed Web of Science ®Google Scholar
• Callejo IP, Brito JA, Bivar JW et al. Predictors of positive axillary lymph nodes in breast cancer patients with metastatic sentinel lymph node. Clin. Transl. Oncol.7(1), 18–22 (2005).
   PubMedGoogle Scholar
• Viale G, Zurrida S, Maiorano E et al. Predicting the status of axillary sentinel lymph nodes in 4351 patients with invasive breast carcinoma treated in a single institution. Cancer103(3), 492–500 (2005).
   PubMed Web of Science ®Google Scholar
• Jonjic N, Mustac E, Dekanic A et al. Predicting sentinel lymph node metastases in infiltrating breast carcinoma with vascular invasion. Int. J. Surg. Pathol.14(4), 306–311 (2006).
   PubMed Web of Science ®Google Scholar
• Kapur U, Rubinas T, Ghai R, Sinacore J, Yao K, Rajan PB. Prediction of nonsentinel lymph node metastasis in sentinel node-positive breast carcinoma. Ann. Diagn. Pathol.11(1), 10–12 (2007).
   PubMed Web of Science ®Google Scholar
• Noguchi M, Katev N, Miyazaki I. Diagnosis of axillary lymph node metastases in patients with breast cancer. Breast Cancer Res. Treat.40(3), 283–293 (1996).
   PubMed Web of Science ®Google Scholar
• Mabry H, Giuliano AE. Sentinel node mapping for breast cancer: progress to date and prospects for the future. Surg. Oncol. Clin. North Am.16(1), 55–70 (2007).
   PubMed Web of Science ®Google Scholar
• Quan ML, McCready D. The evolution of lymph node assessment in breast cancer. J. Surg. Oncol.99(4), 194–198 (2009).
   PubMed Web of Science ®Google Scholar
• Veronesi U, Galimberti V, Zurrida S et al. Sentinel lymph node biopsy as an indicator for axillary dissection in early breast cancer. Eur. J. Cancer37(5), 454–458 (2001).
   PubMed Web of Science ®Google Scholar
• Veronesi U, Paganelli G, Viale G et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N. Engl. J. Med.349(6), 546–553 (2003).
   PubMed Web of Science ®Google Scholar
• Langer I, Guller U, Koechli OR et al. Association of the presence of bone marrow micrometastases with the sentinel lymph node status in 410 early stage breast cancer patients: results of the Swiss Multicenter Study. Ann. Surg. Oncol.14(6), 1896–1903 (2007).
   PubMed Web of Science ®Google Scholar
• Noguchi M. Avoidance of axillary lymph node dissection in selected patients with node-positive breast cancer. Eur. J. Surg. Oncol.34(2), 129–134 (2008).
   PubMed Web of Science ®Google Scholar
• Zavagno G, De Salvo GL, Scalco G et al. A randomized clinical trial on sentinel lymph node biopsy versus axillary lymph node dissection in breast cancer: results of the sentinella/GIVOM trial. Ann. Surg.247(2), 207–213 (2008).
   PubMed Web of Science ®Google Scholar
• Canavese G, Catturich A, Vecchio C et al. Sentinel node biopsy compared with complete axillary dissection for staging early breast cancer with clinically negative lymph nodes: results of randomized trial. Ann. Oncol. (2009) (Epub ahead of print).
   PubMedGoogle Scholar
• Peintinger F, Reitsamer R, Stranzl H, Ralph G. Comparison of quality of life and arm complaints after axillary lymph node dissection vs sentinel lymph node biopsy in breast cancer patients. Br. J. Cancer89(4), 648–652 (2003).
   PubMed Web of Science ®Google Scholar
• Sakorafas GH, Peros G, Cataliotti L, Vlastos G. Lymphedema following axillary lymph node dissection for breast cancer. Surg. Oncol.15(3), 153–165 (2006).
   PubMed Web of Science ®Google Scholar
• Sakorafas GH, Peros G, Cataliotti L. Sequelae following axillary lymph node dissection for breast cancer. Expert Rev. Anticancer Ther.6(11), 1629–1638 (2006).
   PubMed Web of Science ®Google Scholar
• Steegers MA, Wolters B, Evers AW, Strobbe L, Wilder-Smith OH. Effect of axillary lymph node dissection on prevalence and intensity of chronic and phantom pain after breast cancer surgery. J. Pain9(9), 813–822 (2008).
   PubMed Web of Science ®Google Scholar
• Fant JS, Grant MD, Knox SM et al. Preliminary outcome analysis in patients with breast cancer and a positive sentinel lymph node who declined axillary dissection. Ann. Surg. Oncol.10(2), 126–130 (2003).
   PubMed Web of Science ®Google Scholar
• Naik AM, Fey J, Gemignani M et al. The risk of axillary relapse after sentinel lymph node biopsy for breast cancer is comparable with that of axillary lymph node dissection: a follow up study of 4008 procedures. Ann. Surg.240(3), 462–468 (2004).
   PubMed Web of Science ®Google Scholar
• Swenson KK, Mahipal A, Nissen MJ et al. Axillary disease recurrence after sentinel lymph node dissection for breast carcinoma. Cancer104(9), 1834–1839 (2005).
   PubMed Web of Science ®Google Scholar
• Goyal A, Mansel RE. Recent advances in sentinel lymph node biopsy for breast cancer. Curr. Opin. Oncol.20(6), 621–626 (2008).
   PubMed Web of Science ®Google Scholar
• van der Ploeg IM, Tanis PJ, Valdés Olmos RA, Kroon BB, Rutgers EJ, Nieweg OE. Breast cancer patients with extra-axillary sentinel nodes only may be spared axillary lymph node dissection. Ann. Surg. Oncol.15(11), 3239–3243 (2008).
   PubMed Web of Science ®Google Scholar
• Zavagno G, Del Bianco P, Koussis H et al. Clinical impact of false-negative sentinel lymph nodes in breast cancer. Eur. J. Surg. Oncol.34(6), 620–625 (2008).
   PubMed Web of Science ®Google Scholar
• Erb KM, Julian TB. Completion of axillary dissection for a positive sentinel node: necessary or not. Curr. Oncol. Rep.11(1), 15–20 (2009).
   PubMed Web of Science ®Google Scholar
• Ramjeesingh R, Quan ML, Gardner S, Holloway CM. Prediction of involvement of sentinel and nonsentinel lymph nodes in a Canadian population with breast cancer. Can. J. Surg.52(1), 23–30 (2009).
   PubMed Web of Science ®Google Scholar
• Liberman L. Pathologic analysis of sentinel lymph nodes in breast carcinoma. Cancer88(5), 971–977 (2000).
   PubMed Web of Science ®Google Scholar
• Nährig J, Richter T, Kowolik J et al. Comparison of different histopathological methods for examination of sentinel lymph nodes in breast cancer. Anticancer Res.20(3B), 2209–2212 (2000).
   PubMed Web of Science ®Google Scholar
• Weaver DL, Krag DN, Ashikaga T, Harlow SP, O’Connell M. Pathologic analysis of sentinel and nonsentinel lymph nodes in breast carcinoma: a multicenter study. Cancer88(5), 1099–1107 (2000).
   PubMed Web of Science ®Google Scholar
• Groen RS, Oosterhuis AW, Boers JE. Pathologic examination of sentinel lymph nodes in breast cancer by a single haematoxylin-eosin slide versus serial sectioning and immunocytokeratin staining: clinical implications. Breast Cancer Res. Treat.105(1), 1–5 (2007).
   PubMedGoogle Scholar
• Park SY, Kim BH, Kim JH, Lee S, Kang GH. Panels of immnuhistochemical markers help determine primary sites of metastatic adenocarcinoma. Arch. Pathol. Lab. Med.131(10), 1561–1567 (2007).
   PubMed Web of Science ®Google Scholar
• Motomura K, Nagumo S, Komoike Y, Koyama H, Inaji H. Intraoperative imprinting cytology for the diagnosis of sentinel node metastasis in breast cancer. Breast Cancer14(4), 350–353 (2007).
   PubMedGoogle Scholar
• Motomura K, Nagumo S, Komoike Y, Koyama H, Inaji H. Accuracy of imprinting cytology for intraperative diagnosis of sentinel node metastases in breast cancer. Ann. Surg.247(5), 839–842 (2008).
   PubMed Web of Science ®Google Scholar
• Carlsson J, Nordgren H, Sjöström J et al. HER2 expression in breast cancer primary tumours and corresponding metastases. Original data and literature review. Br. J. Cancer90(12), 2344–2348 (2004).
   PubMed Web of Science ®Google Scholar
• Chang E, Lee A, Lee E et al. HER-2/neu oncogene amplification by chromogenic in situ hybridization in 130 breast cancers using tissue microarray and clinical follow-up studies. J. Korean Med. Sci.19(3), 390–396 (2004).
   PubMed Web of Science ®Google Scholar
• Cho EY, Han JJ, Choi YL, Kim KM, Oh YL. Comparison of Her-2, EGFR and cyclin D1 in primary breast cancer and paired metastatic lymph nodes: an immunohistochemical and chromogenic in situ hybridization study. J. Korean Med. Sci.23(6), 1053–1061 (2008).
   PubMed Web of Science ®Google Scholar
• Neumaier M, Gerhard M, Wagener C. Diagnosis of micrometastases by the amplification of tissue-specific genes. Gene159(1), 43–47 (1995).
   PubMed Web of Science ®Google Scholar
• Manzotti M, Dell’Orto P, Maisonneuve P, Zurrida S, Mazzarol G, Viale G. Reverse transcription-polymerase chain reaction assay for multiple mRNA markers in the detection of breast cancer metastases in sentinel lymph nodes. Int. J. Cancer95(5), 307–312 (2001).
   PubMed Web of Science ®Google Scholar
• Krag DN, Weaver DL. Pathological and molecular assessment of sentinel lymph nodes in solid tumors. Semin. Oncol.29(3), 274–279 (2002).
   PubMed Web of Science ®Google Scholar
• Sakaguchi M, Virmani A, Dudak MW et al. Clinical relevance of reverse transcriptase-polymerase chain reaction for the detection of axillary lymph node metastases in breast cancer. Ann. Surg. Oncol.10(2), 117–125 (2003).
   PubMed Web of Science ®Google Scholar
• Backus J, Laughlin T, Wang Y et al. Identification and characterization of optimal gene expression markers for detection of breast cancer metastasis. J. Mol. Diagn.7(3), 327–336 (2005).
   PubMed Web of Science ®Google Scholar
• Abdul-Rasool S, Kidson SH, Panieri E, Dent D, Pillay K, Hanekom GS. An evaluation of molecular markers for improved detection of breast cancer metastases in sentinel nodes J. Clin. Pathol.59(3), 289–297 (2006).
   PubMed Web of Science ®Google Scholar
• Revillion F, Lhotellier V, Hornez L et al. Real time reverse transcription PCR to quantify a panel of 19 genes in breast cancer: relationships with sentinel lymph node invasion. Int. J. Biol. Markers23(1), 10–17 (2008).
   Web of Science ®Google Scholar
• Kurosumi M, Takei H. Significance and problems of histopathological examination and utility of real-time reverse transcriptase-polymerase chain reaction method for the detection of sentinel lymph node metastasis in breast cancer. Breast Cancer14(4), 342–349 (2007).
   PubMedGoogle Scholar
• Nathanson SD, Slater R, Debruyn D, Kapke A, Linden M. Her-2/neu expression in primary breast cancer with sentinel lymph node metastasis. Ann. Surg. Oncol.13(2), 205–213 (2006).
   PubMed Web of Science ®Google Scholar
• Santinelli A, Pisa E, Stramazzotti D, Fabris G. HER-2 status discrepancy between primary breast cancer and metastatic sites. Impact on target therapy. Int. J. Cancer122(5), 999–1004 (2008).
   PubMed Web of Science ®Google Scholar
• Blumencranz P, Whitworth PW, Deck K et al. Scientific Impact Recognition Award. Sentinel node staging for breast cancer: intraoperative molecular pathology overcomes conventional histologic sampling errors. Am. J. Surg.194(4), 426–432 (2007).
   PubMed Web of Science ®Google Scholar
• Julian TB, Blumencranz P, Deck K et al. Novel intraoperative molecular test for sentinel lymph node metastases in patients with early-stage breast cancer. J. Clin. Oncol.26(20), 3338–3345 (2008).
   PubMed Web of Science ®Google Scholar
• Mansel RE, Goyal A, Douglas-Jones A et al. Detection of breast cancer metastasis in sentinel lymph nodes using intra-operative real time GeneSearchtrade mark BLN assay in the operating room: results of the Cardiff study. Breast Cancer Res. Treat. (2008) (Epub ahead of print).
   PubMedGoogle Scholar
• Viale G, Dell’Orto P, Biasi MO et al. Comparative evaluation of an extensive histopathologic examination and a real-time reverse-transcription-polymerase chain reaction assay for mammaglobin and cytokeratin 19 on axillary sentinel lymph nodes of breast carcinoma patients. Ann. Surg.247(1), 136–142 (2008).
   PubMed Web of Science ®Google Scholar
• van Deurzen CH, de Boer M, Monninkhof EM et al. Non-sentinel lymph node metastases associated with isolated breast cancer cells in the sentinel node. J. Natl Cancer Inst.100(22), 1574–1580 (2008).
   PubMedGoogle Scholar
• Vincent-Salomon A, Bidard FC, Pierga JY. Bone marrow micrometastasis in breast cancer: review of detection methods, prognostic impact and biological issues. J. Clin. Pathol.61(5), 570–576 (2008).
   PubMed Web of Science ®Google Scholar
• Wada N, Imoto S. Clinical evidence of breast cancer micrometastasis in the era of the sentinel node biopsy. Int. J. Clin. Oncol.13(1), 24–32 (2008).
   PubMed Web of Science ®Google Scholar
• Reed J, Rosman M, Verbanac KM, Mannie A, Cheng Z, Tafra L. Prognostic implications of isolated tumor cells and micrometastases in sentinel nodes of patients with invasive breast cancer: 10-year analysis of patients enrolled in the prospective East Carolina University/Anne Arundel Medical Center Sentinel Node Multicenter Study. J. Am. Coll. Surg.208(3), 333–340 (2009).
   PubMed Web of Science ®Google Scholar
• Gradishar WJ, Morrow M. Advances in endocrine therapy of metastatic breast cancer. Br. J. Surg.89(12), 1489–1492 (2002).
   PubMed Web of Science ®Google Scholar
• Ellis RL, Seifert PJ, Neal CE et al. Periareolar injection for localization of sentinel nodes in breast cancer patients. Breast J.10(2), 94–100 (2004).
   PubMedGoogle Scholar
• Moore KH, Sweeney KJ, Wilson ME et al. Outcomes for women with ductal carcinoma-in-situ and a positive sentinel node: a multi-institutional audit. Ann. Surg. Oncol.14(10), 2911–2917 (2007).
   PubMed Web of Science ®Google Scholar
• Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer. N. Engl. J. Med.360(8), 790–800 (2009).
   PubMed Web of Science ®Google Scholar
• Perou CM, Sorlie T, Eisen MB et al. Molecular portraits of human breast tumours. Nature406(6797), 747–752 (2000).
   PubMed Web of Science ®Google Scholar
• Sorlie T, Perou CM, Tibshirani R et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl Acad. Sci. USA98(19), 10869–10874 (2001).
   PubMed Web of Science ®Google Scholar
• Bertucci F, Houlgatte R, Benziane A et al. Gene expression profiling of primary breast carcinomas using arrays of candidate genes. Hum. Mol. Genet.9(20), 2981–2999 (2000).
   PubMed Web of Science ®Google Scholar
• Van’t Veer LJ, Dai H, van de Vijver MJ et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature415(6871), 530–536 (2002).
   PubMed Web of Science ®Google Scholar
• van de Vijver MJ, He YD, van’t Veer LJ et al. A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med.347(25), 1999–2009 (2002).
   PubMed Web of Science ®Google Scholar
• Huang E, Cheng SH, Dressman H, et al. Gene expression predictors of breast cancer outcomes. Lancet361 (9369), 1590–1596 (2003).
   PubMed Web of Science ®Google Scholar
• Weigelt B, Glas AM, Wessels LF, Witteveen AT, Peterse JL, van’t Veer LJ. Gene expression profiles of primary breast tumors maintained in distant metastases. Proc. Natl Acad. Sci. USA100(26), 15901–15905 (2003).
   PubMed Web of Science ®Google Scholar
• Weigelt B, Hu Z, He X et al. Molecular portraits and 70-gene prognosis signature are preserved throughout the metastatic process of breast cancer. Cancer Res.65(20), 9155–9158 (2005).
   PubMed Web of Science ®Google Scholar
• Rouzier R, Perou CM, Symmans WF et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin. Cancer Res.11(16), 5678–5685 (2005).
   PubMed Web of Science ®Google Scholar
• Carter SL, Eklund AC, Kohane IS, Harris LN, Szallasi Z. A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers. Nat. Genet.38(9), 1043–1048 (2006).
   PubMed Web of Science ®Google Scholar
• Kapp AV, Jeffrey SS, Langerød A, et al. Discovery and validation of breast cancer subtypes. BMC Genomics7, 231 (2006).
   PubMedGoogle Scholar
• Feng Y, Sun B, Li X et al. Differentially expressed genes between primary cancer and paired lymph node metastases predict clinical outcome of node-positive breast cancer patients. Breast Cancer Res. Treat.103(3), 319–329 (2007).
   PubMed Web of Science ®Google Scholar
• Hu Z, Fan C, Livasy C et al. A compact VEGF signature associated with distant metastases and poor outcomes. BMC Med.7, 9 (2009).
   PubMed Web of Science ®Google Scholar
• Ahr A, Holtrich U, Solbach C et al. Molecular classification of breast cancer patients by gene expression profiling. J. Pathol.195(3), 312–320 (2001).
   PubMed Web of Science ®Google Scholar
• West M, Blanchette C, Dressman H et al. Prediction the clinical status of human breast cancer by using gene expression profiles. Proc. Natl Acad. Sci. USA98(20), 11462–11467 (2001).
   PubMed Web of Science ®Google Scholar
• Ahr A, Karn T, Solbach C et al. Identification of high risk breast-cancer patients by gene expression profiling. Lancet359(9301), 131–132 (2002).
   PubMed Web of Science ®Google Scholar
• Sotiriou C, Neo SY, McShane LM et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc. Natl Acad. Sci. USA100(18), 10393–10398 (2003).
   PubMed Web of Science ®Google Scholar
• Ramaswamy S, Ross KN, Lander ES, Golub TR. A molecular signature of metastasis in primary solid tumors. Nat. Genet.33(1), 49–54 (2003).
   PubMed Web of Science ®Google Scholar
• Lukes L, Crawford NPS, Walker R, Hunter K. The origins of breast cancer prognostic gene expression profiles. Cancer Res.69(1), 310–318 (2009).
   PubMed Web of Science ®Google Scholar
• Hunter KW, Alsarraj J. Gene expression profiles and breast cancer metastasis. Clin. Exp. Metastasis (2009) (Epub ahead of print).
   Google Scholar
• Paik S, Shak S, Tang G et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med.351(27), 2817–2826 (2004).
   PubMed Web of Science ®Google Scholar
• Habel LA, Shak S, Jacobs MK et al. A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients. Breast Cancer Res.8(3), R25 (2006).
   PubMed Web of Science ®Google Scholar
• Kaklamani VG, Gradishar WJ. Gene expression in breast cancer. Curr. Treat. Options Oncol.7(2), 123–128 (2006).
   PubMedGoogle Scholar
• NSABP study confirms Oncotype DX predicts chemotherapy benefit in breast cancer patients. Oncology (Williston Park)20(7), 789–790 (2006).
   PubMed Web of Science ®Google Scholar
• Cronin M, Sangli C, Liu M-L et al. Analytical validation of the Oncotype DX genomic diagnostic test for recurrence prognosis and therapeutic response prediction in node-negative, estrogen receptor-positive breast cancer. Clin. Chem.53(6), 1084–1091(2007).
   PubMed Web of Science ®Google Scholar
• Mina L, Soule SE, Badve S et al. Predicting response to primary chemotherapy: gene expression profiling of paraffin-embedded core biopsy tissue. Breast Cancer Res. Treat.103(2), 197–208 (2007).
   PubMed Web of Science ®Google Scholar
• Glas AM, Floore A, Delahaye LJMJ et al. Converting a breast cancer microarray signature into a high-throughput diagnostic test. BMC Genomics7, 278 (2006).
   PubMed Web of Science ®Google Scholar
• Nuyten DS, van de Vijver MJ. Gene expression signatures to predict the development of metastasis in breast cancer. Breast Dis.26, 149 (2007).
   Google Scholar
• Habermann JK, Doering J, Hautaniemi S et al. The gene expression signature of genomic instability in breast cancer is an independent predictor of clinical outcome. Int. J. Cancer.124(7), 1552–1564 (2009).
   PubMed Web of Science ®Google Scholar
• Sparano JA. TAILORx: trial assigning individualized options for treatment (Rx). Clin. Breast Cancer7(4), 347–350 (2006).
   PubMed Web of Science ®Google Scholar
• Zujewski JA, Kamin L. Trial assessing individualized options for treatment for breast cancer: the TAILORx trial. Future Oncol.4(5), 603–610 (2008).
   PubMed Web of Science ®Google Scholar
• Bogaerts J, Cardoso F, Buyse M et al. Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial. Nat. Clin. Pract. Oncol.3(10), 540–551 (2006).
   PubMedGoogle Scholar
• Cardoso F, Van’t Veer L, Rutgers E, Loi S, Mook S, Piccart-Gebhart MJ. Clinical application of the 70-gene profile: the MINDACT trial. J. Clin. Oncol.26(5), 729–735 (2008).
   PubMed Web of Science ®Google Scholar
• Hyman E, Kauraniemi P, Hautaniemi S et al. Impact of DNA amplification on gene expression patterns in breast cancer. Cancer Res.62(21), 6240–6245 (2002).
   PubMed Web of Science ®Google Scholar
• Pollack JR, Sørlie T, Perou CM et al. Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors. Proc. Natl Acad. Sci. USA99(20), 12963–12968 (2002).
   PubMed Web of Science ®Google Scholar
• De Preter K, Pattyn F, Berx G et al. Combined subtractive cDNA cloning and array CGH: an efficient approach for identification of overexpressed genes in DNA amplicons. BMC Genomics5(1), 11 (2004).
   PubMedGoogle Scholar
• Nessling M, Richter K, Schwaenen C et al. Candidate genes in breast cacner revealed by microarray-based comparative genomic hybridization of archived tissue. Cancer Res.65(2), 439–447 (2005).
   PubMed Web of Science ®Google Scholar
• Adler AS, Lin M, Horlings H, Nuyten DS, van de Vijver MJ, Chang HY. Genetic regulators of large-scale transcriptional signatures in cancer. Nat. Genet.38(4), 421–430 (2006).
   PubMed Web of Science ®Google Scholar
• Bergamaschi A, Kim YH, Wang P et al. Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer. Genes Chrom. Cancer45(11), 1033–1040 (2006).
   PubMed Web of Science ®Google Scholar
• Vincent-Salomon A, Lucchesi C, Gruel N et al. Integrated genomic and transcriptomic analysis of ductal carcinoma in situ of the breast. Clin. Cancer Res.14(7), 1956–1965 (2008).
   PubMed Web of Science ®Google Scholar
• Andre F, Job B, Dessen P et al. Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array. Clin. Cancer Res.15(2), 441–451 (2009).
   PubMed Web of Science ®Google Scholar
• Cheng KW, Lahad JP, Kuo WL et al. The RAB25 small GTPase determines aggressiveness of ovarian and breast cancers. Nat. Med.10(11), 1251–1256 (2004).
   PubMed Web of Science ®Google Scholar
• Ray ME, Zhang ZQ, Albertson D et al. Genomic and expression analysis of the 8p11–12 amplicon in human breast cancer cell lines. Cancer Res.64(1), 40–47 (2004).
   PubMed Web of Science ®Google Scholar
• Garcia MJ, Pole JC, Chin SF et al. A 1 Mb minimal amplicon at 8p11–12 in breast cancer identifies new candidate oncogenes. Oncogene24(33), 5235–5245 (2005).
   PubMed Web of Science ®Google Scholar
• Prentice LM, Shadeo A, Lestou VS et al. NRG1 gene rearrangements in clinical breast cancer: identification of an adjacent novel amplicon associated with poor prognosis. Oncogene24(49), 7281–7289 (2005).
   PubMed Web of Science ®Google Scholar
• Johnson N, Speirs V, Curtin NJ et al. A comparative study of genome-wide SNP, CGH microarray and protein expression analysis to explore genotypic and phenotypic mechanisms of acquired antiestrogen resistance in breast cancer. Breast Cancer Res. Treat.111(1), 55–63 (2008).
   PubMed Web of Science ®Google Scholar
• Koscielny S. Critical review of microarray-based prognostic tests and trials in breast cancer. Curr. Opin. Obstet. Gynecol.20(1), 47–50 (2008).
   PubMed Web of Science ®Google Scholar
• Pfeffer U, Romeo F, Noonan DM, Albini A. Prediction of breast cancer metastasis by genomic profiling: where do we stand?. Clin. Exp. Metastasis (2009) (Epub ahead of print).
   PubMedGoogle Scholar
• Simpson PT, Reis-Filho JS, Gale T, Lakhani SR. Molecular evolution of breast cancer. J. Pathol.205(2), 248–254 (2005).
   PubMed Web of Science ®Google Scholar
• Rennstam K, Hedenfalk I. High-throughput genomic technology in research and clinical management of breast cancer. Molecular signatures of progression from benign epithelium to metastatic breast cancer. Breast Cancer Res.8(4), 213 (2006).
   PubMedGoogle Scholar
• Polyak K. Breast cancer: origins and evolution. J. Clin. Invest.117(11), 3155–3163 (2007).
   PubMed Web of Science ®Google Scholar
• Stingl J, Caldas C. Molecular heterogeneity of breast carcinomas and the cancer stem cell hypothesis. Nat. Rev. Cancer7(10), 791–799 (2007).
   PubMed Web of Science ®Google Scholar
• Hergueta-Redondo M, Palacios J, Cano A et al. New molecular taxonomy in breast cancer. Clin. Transl. Oncol.10(12), 777–785 (2008).
   PubMed Web of Science ®Google Scholar
• Moulis S, Sgroi DC. Re-evaluating early breast neoplasia. Breast Cancer Res.10(1), 302 (2008).
   PubMedGoogle Scholar
• Shipitsin M, Campbell LL, Argani P et al. Molecular definition of breast tumor heterogeneity. Cancer Cell11(3), 259–273 (2007).
   PubMed Web of Science ®Google Scholar
• Weigelt B, Horlings HM, Kreike B et al. Refinement of breast cancer classification by molecular characterization of histological special types. J. Pathol.216(2), 141–150 (2008).
   PubMed Web of Science ®Google Scholar
• Gao Y, Niu Y, Wang X, Wei L, Lu S. Genetic changes at specific stages of breast cancer progression detected by comparative genomic hybridization. J. Mol. Med.87(2), 145–152 (2009).
   PubMed Web of Science ®Google Scholar
• Lengauer C, Kinzler K, Vogelstein B. Genetic instabilities in human cancers. Nature396(6712), 643–649 (1998).
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. The hallmarks of cancer. Cell100(1), 57–70 (2000).
   PubMed Web of Science ®Google Scholar
• Gollin SM. Mechanisms leading to chromosomal instability. Semin. Cancer Biol.15(1), 33–42 (2005).
   PubMed Web of Science ®Google Scholar
• Popescu NC, Zimonjic DB. Chromosome and gene alterations in breast cancer as markers for diagnosis and prognosis as well as pathogenetic targets for therapy. Am. J. Med. Genet.115(3), 142–149 (2002).
   PubMed Web of Science ®Google Scholar
• Teixeira MR. Combined classical and molecular cytogenetic analysis of cancer. Eur. J. Cancer38(12), 1580–1584 (2002).
   PubMed Web of Science ®Google Scholar
• Albertson DG, Collins C, McCormick F, Gray JW. Chromosome aberrations in solid tumors. Nat. Genet.34(4), 369–376 (2003).
   PubMed Web of Science ®Google Scholar
• Keen-Kim D, Nooraie F, Rao PN. Cytogenetic biomarkers for human cancer. Front. Biosci.13, 5928–5949 (2008).
   PubMed Web of Science ®Google Scholar
• Teixeira MR, Tsarouha H, Kraggerud SM et al. Evaluation of breast cancer polyclonality by combined chromosome banding and comparative genomic hybridization analysis. Neoplasia3(3), 204–214 (2001).
   PubMed Web of Science ®Google Scholar
• Kallioniemi A, Kallioniemi OP, Piper J et al. Detection and mapping of amplified DNA sequences in breast cancer by comparative genomic hybridization. Proc. Natl Acad. Sci. USA91(6), 2156–2160 (1994).
   PubMed Web of Science ®Google Scholar
• Pinkel D, Segraves R, Sudar D et al. High resolution analysis of DNA copy number variation using comparative genomic hybridization to microarrays. Nat. Genet.20(2), 207–211 (1998).
   PubMed Web of Science ®Google Scholar
• Pollack JR, Perou CM, Alizadeh AA et al. Genome-wide analysis of DNA copy-number changes using cDNA microarrays. Nat. Genet.23(1), 41–46 (1999).
   PubMed Web of Science ®Google Scholar
• Ylstra B, van den Ijssel P, Carvalho M et al. BAC to the future! or oligonucleotides: a perspective for micro array comparative genomic hybridization (array CGH). Nucleic Acids Res.34(2), 445–450 (2006).
   PubMed Web of Science ®Google Scholar
• Bentley DR. Whole-genome re-sequencing. Curr. Opin. Genet. Dev.16(6), 545–552 (2006).
   PubMed Web of Science ®Google Scholar
• Shaffer C. Next-generation sequencing outpaces expectations. Nat. Biotechnol.25(2), 149 (2007).
   PubMed Web of Science ®Google Scholar
• Reis-Filho JS, Simpson PT, Gale T, Lakhani SR. The molecular genetics of breast cancer: the contribution of comparative genomic hybridization. Pathol. Res. Pract.201(11), 713–725 (2005).
   PubMed Web of Science ®Google Scholar
• van Beers EH, Nederlof PM. Array-CGH and breast cancer. Breast Cancer Res.8(3), 210 (2006).
   PubMedGoogle Scholar
• Climent J, Garcia JL, Mao JH, Arsuaga J, Perez-Losada J. Characterization of breast cancer by array comparative genomic hybridization. Biochem. Cell Biol.85(4), 497–508 (2007).
   PubMedGoogle Scholar
• Emerson JC, Salmon SE, Dalton W et al. Cytogenetics and clinical correlations in breast cancer. Adv. Exp. Med. Biol.330, 107–118 (1993).
   PubMedGoogle Scholar
• Pandis N, Heim S, Bardi G, Idvall I, Mandahl N, Mitelman F. Chromosome analysis of 20 breast carcinomas: cytogenetic multiclonality and karyotypic-pathologic correlations. Genes Chrom. Cancer6(1), 51–57 (1993).
   PubMed Web of Science ®Google Scholar
• Herrington CS, Leek RD, McGee JO. Correlation of numerical chromosome 11 and 17 imbalance with metastasis of primary breast cancer to lymph nodes. J. Pathol.176(4), 353–359 (1995).
   PubMed Web of Science ®Google Scholar
• Pandis N, Idvall I, Bardi G et al. Correlation between karyotypic pattern and clincopathologic features in 125 breast cancer cases. Int. J. Cancer66(2), 191–196 (1996).
   PubMed Web of Science ®Google Scholar
• Simpson JF, Quan DE, Ho JP et al. Genetic heterogeneity of primary and metastatic breast carcinoma defined by fluorescence in situ hybridization. Am. J. Pathol.149(3), 751–758 (1996).
   PubMed Web of Science ®Google Scholar
• Cavalli LR, Cavaliéri LM, Ribeiro LA, Cavalli IJ, Silveira R, Rogatto SR. Cytogenetic evaluation of 20 primary breast carcinomas. Hereditas126(3), 261–268 (1997).
   PubMed Web of Science ®Google Scholar
• Adeyinka A, Mertens F, Ivall I et al. Cytogenetic heterogeneity and clonal evolution in synchronous bilateral breast carcinomas and their lymph node metastases from a male patient without any detectable BRCA2 germline mutation. Cancer Genet. Cytogenet.118(1), 42–47 (2000).
   PubMedGoogle Scholar
• Wuicik L, Cavalli LR, Cornélio DA et al. Chromosome alterations associated with positive and negative lymph node involvement in breast cancer. Cancer Genet. Cytogenet.173(2), 114–221 (2007).
   PubMedGoogle Scholar
• Piao Z, Malkhosyan SR. Frequent loss Xq25 on the inactive X chromosome in primary breast carcinomas is associated with tumor grade and axillary lymph node metastasis. Genes Chrom. Cancer33(3), 262–269 (2002).
   PubMed Web of Science ®Google Scholar
• Isola JJ, Kallioniemi OP, Chu LW et al. Genetic aberrations detected by comparative genomic hybridization predict outcome in node-negative breast cancer. Am. J. Pathol.147(4), 905–911 (1995).
   PubMed Web of Science ®Google Scholar
• Aubele M, Auer G, Nährig J et al. Chromosomal imbalances are associated with metastasis-free survival in breast cancer patients. Anal. Cell Pathol.24(2–3), 77–87 (2002).
   PubMed Web of Science ®Google Scholar
• Climent J, Martinez-Climent JA, Garcia-Barchino MJ et al. Genomic loss of 18p predicts an adverse clinical outcome in patients with high-risk breast cancer. Clin. Cancer Res.8(12), 3863–3869 (2002).
   PubMed Web of Science ®Google Scholar
• Dellas A, Torhorst J, Schiltheiss E et al. DNA sequence losses on chromosomes 11p and 18q are associated with clinical outcome in lymph node-negative ductal breast cancer. Clin. Cancer Res.8(5), 1210–1216 (2002).
   PubMed Web of Science ®Google Scholar
• Karlsson E, Danielsson A, Delle U, Olsson B, Karlsson P, Helou K. Chromosomal changes associated with clinical outcome in lymph node-negative breast cancer. Cancer Genet. Cytogenet.172(2), 139–146 (2007).
   PubMedGoogle Scholar
• Chin SF, Wang Y, Thorne NP et al. Using array-comparative genomic hybridization to define molecular portraits of primary breast cancers. Oncogene26(13), 1959–1970 (2007).
   PubMed Web of Science ®Google Scholar
• Hermsen MA, Baak JP, Meijer GA et al. Genetic analysis of 53 lymph node-negative breast carcinomas by CGH and relation to clinical, pathological, morphometric, and DNA cytometric prognostic factors. J. Pathol.186(4), 356–362 (1998).
   PubMedGoogle Scholar
• Seute A, Sinn HP, Schlenk RF et al. Clinical relevance of genomic aberrations in homogeneously treated high-risk stage II/III breast cancer patients. Int. J. Cancer93(1), 80–84 (2001).
   PubMed Web of Science ®Google Scholar
• Hislop RG, Pratt N, Stocks SC et al. Karyotypic aberrations of chromosomes 16 and 17 are related to survival in patients with breast cancer. Br. J. Surg.89(12), 1581–1586 (2002).
   PubMed Web of Science ®Google Scholar
• Zudaire I, Odero MD, Caballero C et al. Genomic imbalances detected by comparative genomic hybridization are prognostic markers in invasive ductal breast carcinomas. Histopathology40(6), 547–555 (2002).
   PubMed Web of Science ®Google Scholar
• Janssen EA, Baak JP, Guervós MA, van Diest PJ, Jiwa M, Hermsen MA. In lymph node-negative invasive breast carcinomas, specific chromosomal aberrations are strongly associated with high mitotic activity and predict outcome more accurately than grade, tumor diameter, and oestrogen receptor. J. Pathol.201(4), 555–561 (2003).
   PubMed Web of Science ®Google Scholar
• Bednarek AK, Laflin KJ, Daniel RL, Liao Q, Hawkins KA, Aldaz CM. WWOX, a novel domain-containing protein mapping to human chromosome 16q23.3–24.1, a region frequently affected in breast cancer. Cancer Res.60(8), 2140–2145 (2000).
   PubMed Web of Science ®Google Scholar
• Tanner MM, Tirkkonen M, Kallioniemi A et al. Amplification of chromosomal region 20q13 in invasive breast cancer: prognostic implications. Clin. Cancer Res.1(12), 1455–1461 (1995).
   PubMed Web of Science ®Google Scholar
• Deng G, Yu M, Chen LC, Moore D et al. Amplification of oncogene erbB-2 and chromosome 20q in breast cancer determined by differentially competitive polymerase chain reaction. Breast Cancer Res. Treat.40(3), 271–281 (1996).
   PubMed Web of Science ®Google Scholar
• Man Y-G, Fu SW, Schwartz A, Pinzone JJ, Simmens SJ, Berg PE. Expression of BP1, a novel homeobox gene, correlates with breast cancer progression and invasion. Breast Cancer Res. Treat.90(3), 241–247 (2005).
   PubMed Web of Science ®Google Scholar
• Mano MS, Rosa DD, De Azambuja E, Ismael GF, Durbecq V. The 17q12–q21 amplicon: Her2 and topoisomerase-IIα and their importance to the biology of solid tumours. Cancer Treat. Rev.33(1), 64–77 (2007).
   PubMed Web of Science ®Google Scholar
• Cavalli LR, Man Y-G, Schwartz AM et al. Amplification of the BP1 homeobox gene in breast cancer. Amplification of the BP1 homeobox gene in breast cancer. Cancer Genet. Cytogenet.187, 19–24 (2008).
   PubMedGoogle Scholar
• Nagahata T, Hirano A, Utada Y et al. Correlation of allelic losses and clinicopathogical factors in 504 primary breast cancers. Breast Cancer9(3), 208–215 (2002).
   PubMedGoogle Scholar
• Kominsky SL, Argani P, Korz D et al. Loss of the tight junction protein claudin-7 correlates with histological grade in both ductal carcinoma in situ and invasive ductal carcinoma of the breast. Oncogene22(13), 2021–2033 (2003).
   PubMed Web of Science ®Google Scholar
• Klebig C, Seitz S, Korsching E et al. Profile of differentially expressed genes after transfer of chromosome 17 into the breast cancer cell line CAL51. Genes Chrom. Cancer44(3), 233–246 (2005).
   PubMed Web of Science ®Google Scholar
• Morikawa A, Williams TY, Dirix L et al. Allelic imbalances of chromosomes 8p and 18q and their roles in distant relapse of early stage, node-negative breast cancer. Breast Cancer Res.7(6), R1051–R1057 (2005).
   Google Scholar
• Malinowski DP. Multiple biomarkers in molecular oncology. II. Molecular diagnostics applications in breast cancer management. Expert Rev. Mol. Diagn.7(3), 269–280 (2007).
   PubMed Web of Science ®Google Scholar
• Ellsworth RE, Ellsworth DL, Patney HL et al. Genomic alterations associated with early stages of breast tumor metastasis. Ann. Surg. Oncol.15(7), 1989–1995 (2008).
   PubMed Web of Science ®Google Scholar
• Pasche B. Recent advances in breast cancer genetics. Cancer Treat. Res.141, 1–10 (2008).
   PubMedGoogle Scholar
• Kuukasjarvi T, Karhu R, Tanner M et al. Genetic heterogeneity and clonal evolution underlying development of asynchronous metastasis in human breast cancer. Cancer Res.57(8), 1597–1604 (1997).
   PubMed Web of Science ®Google Scholar
• Nishizaki T, DeVries S, Chew K et al. Genetic alterations in primary breast cancers and their metastases: direct comparison using modified comparative genomic hybridization. Genes Chrom. Cancer19(4), 267–272 (1997).
   PubMed Web of Science ®Google Scholar
• Teixeira MR, Pandis N, Heim S. Cytogenetic clues to breast carcinogenesis. Genes Chrom. Cancer33(1), 1–16 (2002).
   PubMed Web of Science ®Google Scholar
• Weber-Mangal S, Sinn HP, Popp S et al. Breast cancer in young women (<or=35 years): genomic aberrations detected by Comparative Genomic Hybridization. Int. J. Cancer107(4), 583–592 (2003).
   PubMed Web of Science ®Google Scholar
• Torres L, Ribeiro FR, Pandis N, Andersen JA, Heim S, Teixeira MR. Intratumor genomic heterogeneity in breast cancer with clonal divergence between primary carcinomas and lymph node metastases. Breast Cancer Res. Treat.102(2), 143–155 (2007).
   PubMed Web of Science ®Google Scholar
• Friedrich K, Weber T, Scheithauer J et al. Chromosomal genotype in breast cancer progression: comparison of primary and secondary manifestations. Cell Oncol.30(1), 39–50 (2008).
   PubMed Web of Science ®Google Scholar
• Han W, Han MR, Kang JJ et al. Genomic alterations identified by array comparative genomic hybridization as prognostic markers in tamoxifen-treated estrogen receptor-positive breast cancer. BMC Cancer6, 92 (2006).
   PubMedGoogle Scholar
• Zafrani B, Gerbault-Seureau M, Mosseri V, Dutrillaux B. Cytogenetic study of breast cancer: clinicopathologic significance of homogeneously staining regions in 84 patients. Hum. Pathol.23(5), 542–547 (1992).
   PubMed Web of Science ®Google Scholar
• Tsuda H, Takarabe T, Fukutomi T, Hirohashi S. der(16)t(1;16)/der(1;16) in breast cancer detected by fluorescence in situ hybridization is an indicator of better patient prognosis. Genes Chrom. Cancer.24(1), 72–77 (1999).
   PubMed Web of Science ®Google Scholar
• Cavalli LR, Urban CA, Dai D et al. Genetic and epigenetic alterations in sentinel lymph nodes metastatic lesions compared to their corresponding primary breast tumors. Cancer Genet. Cytogenet.146(1), 33–40 (2003).
   PubMedGoogle Scholar
• Santos SCL, Cavalli IJ, Ribeiro EMSF et al. Patterns of DNA copy number changes in sentinel lymph node breast cancer metastasis. Cytog. Genome Res.122(1), 16–21 (2008).
   PubMed Web of Science ®Google Scholar
• Schmidt-Kittler O, Ragg T, Daskalakis A et al. From latent disseminated cells to overt metastasis: genetic analysis of systemic breast cancer progression. Proc. Natl Acad. Sci. USA100(13), 7737–772 (2003).
   PubMed Web of Science ®Google Scholar
• Li J, Gromov P, Gromova I et al. Omics-based profiling of carcinoma of the breast and matched regional lymph node metastasis. Proteomics8(23–24), 5038–5052 (2008).
   PubMed Web of Science ®Google Scholar
• Redon R, Ishikawa S, Fitch KR et al. Global variation in copy number in the human genome. Nature444(7118), 444–454 (2006).
   PubMed Web of Science ®Google Scholar